Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries. There is currently a large unmet need for a safe, early intervention therapeutic that provides protection to brain cells immediately following a stroke, until the underlying cause of stroke can be diagnosed and alleviated.
It is our mission to provide a solution for this unmet need. Our aim is for ARG-007 to be administered by first responders in the field to provide neuroprotective treatment prior to a patient’s arrival at the hospital which will result in improved patient outcomes.
Chief Executive Officer: Dr Liz Dallimore
Dr Dallimore has over 20 years’ experience in both biotechnology and management consulting across Australia and the UK. She has held senior roles in management consulting as KPMG’s Australian Director of Research Engagement and Commercialisation, structuring technology commercialisation deals across a range of sectors, with a specific focus on biotechnology.
Prior to this Liz held senior management roles with Ernst & Young and Price water house Coopers in technology advisory and R&D. Prior to moving into management consulting, Liz was a research scientist at the Australian Neuromuscular Research Institute (now the Perron Institute of Neurological & Translational Sciences) and the UK’s Food Standard’s Agency.
Dr Dallimore is also a Non-Executive director of the Chamber of Commerce and Industry WA and AusBiotech, as well as and Industry Advisor to the Telethon Kids Institute’s Innovation and Commercialisation Committee and member of the Stan Perron Charitable Foundation’s Health Research Advisory Panel advising on child health research funding.
Dr Dallimore holds a PhD in Neuroscience jointly completed at Oxford University and the University of Western Australia, an MBA from the Australian Graduate School of Management, and is a Member of the Australian Institute of Company Directors.
Latest News
Argenica Therapeutics (ASX:AGN) strategic leap in neonatal brain protection gains FDA’s support
With FDA Orphan Drug and Rare Pediatric Disease designations, Argenica Therapeutics (ASX:AGN) strengthens its path forward for ARG-006, a promising treatment for neonatal brain injuries in hypoxic-ischaemic encephalopathy (HIE).
Argenica Therapeutics (ASX:AGN) poised for IND milestone: key safety studies propel ARG-007’s competitive edge
ARG-007’s unique mechanism of action and proven safety profile position it as a strong contender in the acute ischaemic stroke treatment landscape.
Argenica Therapeutics (ASX:AGN) pioneers breakthroughs in neuroprotection with ARG-007
Argenica Therapeutics is advancing its novel neuroprotective drug ARG-007 through a promising Phase 2 trial, with no adverse events reported and potential applications in multiple neurological conditions.
Argenica (ASX:AGN) continues on pace for pivotal Australian stroke trials
Pivotal trials which could position an Australian therapeutic as a leading candidate in the fight against stroke continue on pace.
Argenica (ASX:AGN) provides more proof of traumatic brain injury reduction
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
Argenica (ASX:AGN) stroke drug judged safe for continued efficacy testing
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
